StreetInsider.com News Articles

Form 4 ALUMIS INC. For: May 22 Filed by: Drappa Jorn

Wed, 27 May 2026 19:07:00 -0400

si-local-file:///var/storage/secattach/20260527/26559559.html

Form 4 ALUMIS INC. For: May 22 Filed by: Drappa Jorn

Wed, 27 May 2026 19:07:00 -0400

si-local-file:///var/storage/secattach/20260527/26559559.html

Form ARS ALUMIS INC. For: Dec 31

Mon, 18 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260518/26514320.html

Form ARS ALUMIS INC. For: Dec 31

Mon, 18 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260518/26514320.html

Form DEFA14A ALUMIS INC.

Mon, 18 May 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260518/26514286.html

Form DEFA14A ALUMIS INC.

Mon, 18 May 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260518/26514286.html

Form DEF 14A ALUMIS INC. For: Jun 30

Mon, 18 May 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260518/26514262.html

Form DEF 14A ALUMIS INC. For: Jun 30

Mon, 18 May 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260518/26514262.html

Alumis Inc (ALMS) PT Raised to $39 at Morgan Stanley

Fri, 15 May 2026 08:43:12 -0400

Morgan Stanley analyst Terence Flynn raised the price target on Alumis Inc (NASDAQ: ALMS) to $39.00 (from $38.00) while maintaining a Overweight rating.

Stifel on Alumis Inc (ALMS): 'upcoming Ph2b data in SLE in 3Q26 represent the most important near-term catalyst for the stock'

Fri, 15 May 2026 07:56:31 -0400

Stifel analyst Alex Thompson reiterated a Buy rating and $44.00 price target on Alumis Inc (NASDAQ: ALMS)

The analyst comments "We are reiterating our Buy rating following ALMS' 1Q26 update. Following full Ph3 envudeucitinib (TYK2) data at AAD in March--which showed robust and consistent topline PASI responses with continued deepening through week-24--ALMS plans to file their NDA submission in 4Q26 (narrowed from 2H26)--longer-term data expected in 2H26. Data here were comparable/better vs. TAK's zasocitinib and JNJ's Icotyde (IL-23R) and set up well into the evolving psoriasis landscape. That said, given the expected competitive nature of the next-gen oral market in psoriasis,

Alumis Inc (ALMS) PT Raised to $34 at Guggenheim

Fri, 15 May 2026 06:42:16 -0400

(Updated - May 15, 2026 6:42 AM EDT)

Guggenheim analyst Yatin Suneja raised the price target on Alumis Inc (NASDAQ: ALMS) to $34.00 (from $32.00) while maintaining a Buy rating.

The analyst commented: 'Key takeaways from the ALMS 1Q26 earnings release are: (1) ALMS presented detailed results of envudeucitinib ("envu"; oral TYK2i) in the Phase III ONWARD1&2 studies (n=840/study) in psoriasis (PsO) at AAD 2026, showing competitive PASI 90/100 and sPGA-0/1 response rates at Weeks 16 and 24 (Exhibit 1), as well as a well-tolerated safety profile (Exhibit 2). We found these data meeting/ exceeding expectations, with potential differentiation vs. TAK's zasocitinib

Alumis Inc (ALMS) PT Raised to $34 at Guggenheim

Fri, 15 May 2026 06:42:16 -0400

(Updated - May 15, 2026 6:42 AM EDT)

Guggenheim analyst Yatin Suneja raised the price target on Alumis Inc (NASDAQ: ALMS) to $34.00 (from $32.00) while maintaining a Buy rating.

Alumis Inc (ALMS) PT Raised to $51 at Wells Fargo

Fri, 15 May 2026 06:28:48 -0400

Wells Fargo analyst Derek Archila raised the price target on Alumis Inc (NASDAQ: ALMS) to $51.00 (from $49.00) while maintaining a Overweight rating.

H.C. Wainwright Downgrades Alumis Inc (ALMS) to Neutral

Fri, 15 May 2026 06:11:33 -0400

H.C. Wainwright analyst Mitchell S. Kapoor downgraded Alumis Inc (NASDAQ: ALMS) from Buy to Neutral.

For an analyst ratings summary and ratings history on Alumis Inc click here. For more ratings news on Alumis Inc click here.

Shares of Alumis Inc closed at $24.63 yesterday.

Form 10-Q ALUMIS INC. For: Mar 31

Thu, 14 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260514/26495269.html

Form 10-Q ALUMIS INC. For: Mar 31

Thu, 14 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260514/26495269.html

Form 8-K ALUMIS INC. For: May 14

Thu, 14 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260514/26494880.html

Form 8-K ALUMIS INC. For: May 14

Thu, 14 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260514/26494880.html

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

Thu, 14 May 2026 16:05:00 -0400

– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –

– Data showed robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) –

– Data continue to underscore envudeucitinib’s potential as a leading oral therapy for PsO; plans to submit NDA in 4Q 2026 remain on track –

– Potentially pivotal

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

Thu, 14 May 2026 16:05:00 -0400

– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –

– Data showed robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) –

– Data continue to underscore envudeucitinib’s potential as a leading oral therapy for PsO; plans to submit NDA in 4Q 2026 remain on track –

– Potentially pivotal

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

Thu, 14 May 2026 16:05:00 -0400

– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –

– Data showed robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) –

– Data continue to underscore envudeucitinib’s potential as a leading oral therapy for PsO; plans to submit NDA in 4Q 2026 remain on track –

– Potentially pivotal

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

Thu, 14 May 2026 16:05:00 -0400

– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –

– Data showed robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) –

– Data continue to underscore envudeucitinib’s potential as a leading oral therapy for PsO; plans to submit NDA in 4Q 2026 remain on track –

– Potentially pivotal

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

Thu, 14 May 2026 16:05:00 -0400

– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –

– Data showed robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) –

– Data continue to underscore envudeucitinib’s potential as a leading oral therapy for PsO; plans to submit NDA in 4Q 2026 remain on track –

– Potentially pivotal

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

Thu, 14 May 2026 16:05:00 -0400

– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –

– Data showed robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) –

– Data continue to underscore envudeucitinib’s potential as a leading oral therapy for PsO; plans to submit NDA in 4Q 2026 remain on track –

– Potentially pivotal

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

Thu, 14 May 2026 16:05:00 -0400

– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –

– Data showed robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) –

– Data continue to underscore envudeucitinib’s potential as a leading oral therapy for PsO; plans to submit NDA in 4Q 2026 remain on track –

– Potentially pivotal